With an age cutoff for a new gene therapy, families and doctors scramble to treat kids before their 6th birthday

In July, Kristen Secrist (above, center) hopped on a call with her 5-year-old son's doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time. Read more.

By Jason Mast

Mike Reddy for STAT

Health care CEOs hauled in $4 billion last year as inflation pinched workers, analysis shows

The health care industry didn't just provide a safe haven for jittery stock investors in 2022, a year defined by inflation and higher interest rates. It also provided a stable stream of wealth for top executives, who collectively pocketed billions of dollars in what was otherwise a rough patch for the economy. Read more.

By Bob Herman, J. Emory Parker, Adam Feuerstein, Lizzy Lawrence, and Mohana Ravindranath

Michelle Gable for STAT

Why drug shortages are having an outsize impact on ovarian cancer patients

While patients with various types of cancer have been impacted by drug shortages, those with ovarian cancer, like Sarah Evans (above), are among the groups most affected — both because the disease is relatively common and because the drugs that are most effective in treating it are the ones now in short supply. Read more.

By Annalisa Merelli

More great reads from STAT this week

Hospitals are dialing back on venture capital investing
Radiation, a mainstay of cancer treatment, begins a fade-out
Opinion: I'm a dentist. I'm begging people not to give up on aspartame
Why so few get screened for lung cancer, the deadliest cancer in the U.S.
New definition of a human embryo proposed amid rapid scientific advances
Listen: How Long Island became the 'eugenics capital of the world'
Matt's Take: From drug shortages to high prices, U.S. system's shortcomings have deep roots